SELLAS Life Sciences Group Inc
SLSHealthcare|Biotechnology|USA
$12.76
-0.74 (-5.52%)
Tangible Book
$0.58
Earnings Power
$6.03
Upcoming Data Readouts (1)
Dec 2026
Est. completion
P1P2Hematologic Malignancies
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
NCT04588922n=160
Awaiting Results (1)
Trials past primary completion date but still active — data readout may be imminent.
Dec 2025
P3
Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2
NCT04229979